会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明公开
    • Functionalized peptidyl aminodiols and -triols
    • 功能性磷酸二肽和 -
    • EP0230266A3
    • 1990-01-17
    • EP87100422.2
    • 1987-01-15
    • ABBOTT LABORATORIES
    • Rosenberg, Saul HowardPlattner, Jacob JohnLuly, Jay Richard
    • C07K5/06C07K5/02C07K5/08C07D233/64A61K31/415A61K37/02A61K37/64
    • C07D233/64A61K38/00C07K5/0227C07K5/06043C07K5/06078C07K5/0806
    • The invention relates to renin inhibiting compounds of the formula
      wherein A is hydrogen; loweralkyl; arylalkyl; OR₈ or SR₈ wherein R₈ is hydrogen, loweralkyl or aminoalkyl; NR₉R₁₀ wherein R₉ and R₁₀ are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl;
      wherein B is NH, alkylamino, S, O, CH₂ or CHOH and R₁₁ is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxy­alkyl)(alkyl)amino, carboxylic acid-substituted alkyl, alkoxycarbonylalkyl, aminoalkyl, N-protected aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (N-protected)­ alkyl)aminoalkyl, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic; R₁ is loweralkyl, cycloalkylmethyl, benzyl, α-methylbenzyl, α, α-di­methylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)­methyl, (2-naphthyl)methyl, (4-imidazoyl)methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R₁ is phenoxy, thiophenoxy or anilino, B is CH₂ or CHOH or A is hydrogen; R₃ is loweralkyl, benzyl or heterocyclic ring-substituted methyl; R₄ is lower­alkyl, cycloalkyl- methyl or benzyl; R₂, R₅ and R₆ are independently hydrogen or loweralkyl; X is O, NH or S; R₇ is hydrogen, loweralkyl, alkanoyl, alkylsulfonyl.
      wherein R₁₂ and R₁₃ are independently hydrogen or loweralkyl, n is 0-2 and R₁₄ is substituted or unsubstituted penyl or heterocyclic; or XR₇ together are loweralkylsulfonyl, N₃ or Cl, and pharmaceutically acceptable salts thereof.
    • 3. 发明公开
    • Peptidylaminodiols
    • EP0229667A2
    • 1987-07-22
    • EP87100424.8
    • 1987-01-15
    • ABBOTT LABORATORIES
    • Luly, Jay RichardKempf, Dale JohnPlattner, Jacob John
    • C07K5/06C07K5/08C07K5/02C07D233/64C07C237/12A61K31/415A61K37/02A61K37/64A61K31/16
    • C07D233/64A61K38/00C07K5/0202C07K5/0227C07K5/06026C07K5/06043C07K5/0606C07K5/06078C07K5/0806C07K5/0808C07K5/0821C07K5/0823Y02P20/55
    • A renin inhibiting compound of the formula:
      wherein A is a substituent; W is C=O or CHOH; U is CH₂ or NR₂, provided that when W is CHOH then U is CH₂; R₁ is loweralkyl, cycloalkylmethyl, benzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)methyl, (2-naphthyl)methyl, (4-imidazoyl)methyl, α, α -dimethylbenzyl, 1-benzyloxyethyl, phenethyl, phenoxy, thiophenoxy or anilino; R₂ is hydrogen or loweralkyl; R₃ is loweralkyl, [(alkoxy)alkoxy]alkyl, (thioalkoxy)alkyl, lowerakenyl, benzyl or heterocyclic ring substituted methyl; R₄ is loweralkyl, cycloalkylmethyl or benzyl; R₅ is vinyl, formyl, hydroxymethyl or hydrogen; R₇ is hydrogen or loweralkyl; R₈ and R₉ are independently selected from OH and NH₂; and R₆ is hydrogen, loweralkyl, vinyl or arylalkyl; provided that when R₅ and R₇ are both hydrogen and R₈ and R₉ are OH, the carbon bearing R₅ is of the "R" configuration and the carbon bearing R₆ is of the "S" configuration; or pharmaceutically acceptable salts or esters thereof. Also disclosed are renin inhibiting compositions, a method of treating hypertension, methods of making the renin inhibiting compounds and intermediates useful in making the renin inhibiting compounds.
    • 一种下式的肾素抑制化合物:其中A是取代基; W是C = O或CHOH; U是CH 2或NR 2,条件是当W是CHOH时,则U是CH 2; (1-萘基)甲基,(2-萘基)甲基,(4-咪唑基)甲基,α,α-二甲基苄基,1-苄氧基乙基,苯乙基,苯氧基,硫代苯氧基(低级烷基) 或苯胺基; R 2是氢或低级烷基; R 3是低级烷基,[(烷氧基)烷氧基]烷基,(硫代烷氧基)烷基,低级链烯基,苄基或杂环取代的甲基; R 4是低级烷基,环烷基甲基或苄基; R 5是乙烯基,甲酰基,羟甲基或氢; R 7是氢或低级烷基; R 7和R 7独立地选自OH和NH 2; 和R 6是氢,低级烷基,乙烯基或芳基烷基; 条件是当R 5和R 7都是氢而R 7和R 7是OH时,带有R 5的碳是“R”构型,带有R 6的碳是“S”构型; 或其药学上可接受的盐或酯。 还公开了肾素抑制组合物,治疗高血压的方法,制备肾素抑制化合物和中间体用于制备肾素抑制化合物的方法。
    • 4. 发明公开
    • Peptidylaminodiols
    • Peptidylaminodiole。
    • EP0189203A2
    • 1986-07-30
    • EP86100917.3
    • 1986-01-23
    • ABBOTT LABORATORIES
    • Luly, Jay RichardPlattner, John JacobRosenberg, Saul HowardFung, Anthony K.L.
    • C07K5/06C07D233/64A61K37/64
    • C07K5/06078A61K38/00C07K5/0227C07K5/06017C07K5/06139Y02P20/55
    • The invention relates to renin inhibiting compounds of the formula:
      wherein R 10 is
      A is hydrogen or an N-protecting group; w is 0 or 1; B is hydrogen, hydroxy, NH, N-alkyl, loweralkyl or arylalkyl; with the proviso that when w is 1, B is NH and when w is 0, B is hydrogen, hydroxy, loweralkyl or arylalkyl; R 1 is loweralkyl or lipophilic or aromatic or hydrophilic amino acid side chains; m is 1-3; n is 1-3; p is 1-3; q is 1-3; s is 1-3; t is 0-2; R 2 is hydrogen or loweralkyl; R 3 and R 4 are independently selected from loweralkyl, lipophilic or aromatic amino acid side chains; R 5 and R 7 are independently selected from hydrogen or loweralkyl; and R 6 is hydrogen, loweralkyl, vinyl, arylalkyl or wherein R 8 is hydrogen or loweralkyl, X is O, NH or S and R 9 is hydrogen, loweralkyl or alkanoyl or XR 9 together can be loweralkylsulfonyl, N 3 or Cl.
    • 本发明涉及下式的肾素抑制化合物:其中R 10是氢或N-保护基; w为0或1; B是氢,羟基,NH,N-烷基,低级烷基或芳基烷基; 条件是当w为1时,B为NH,当w为0时,B为氢,羟基,低级烷基或芳基烷基; R1是低级烷基或亲脂性或芳族或亲水氨基酸侧链; m为1-3; n为1-3; p为1-3; q为1-3; s是1-3; t为0-2; R2是氢或低级烷基; R3和R4独立地选自低级烷基,亲脂性或芳族氨基酸侧链; R5和R7独立地选自氢或低级烷基; 并且R 6是氢,低级烷基,乙烯基,芳烷基或其中R 8是氢或低级烷基,X是O,NH或S,R 9是氢,低级烷基或烷酰基或X R 9一起可以是低级烷基磺酰基,N 3或Cl。
    • 6. 发明公开
    • Peptidylaminodiols
    • EP0189203A3
    • 1989-08-23
    • EP86100917.3
    • 1986-01-23
    • ABBOTT LABORATORIES
    • Luly, Jay RichardPlattner, John JacobRosenberg, Saul HowardFung, Anthony K.L.
    • C07K5/06C07D233/64A61K37/64
    • C07K5/06078A61K38/00C07K5/0227C07K5/06017C07K5/06139Y02P20/55
    • The invention relates to renin inhibiting compounds of the formula:
      wherein R 10 is
      A is hydrogen or an N-protecting group; w is 0 or 1; B is hydrogen, hydroxy, NH, N-alkyl, loweralkyl or arylalkyl; with the proviso that when w is 1, B is NH and when w is 0, B is hydrogen, hydroxy, loweralkyl or arylalkyl; R 1 is loweralkyl or lipophilic or aromatic or hydrophilic amino acid side chains; m is 1-3; n is 1-3; p is 1-3; q is 1-3; s is 1-3; t is 0-2; R 2 is hydrogen or loweralkyl; R 3 and R 4 are independently selected from loweralkyl, lipophilic or aromatic amino acid side chains; R 5 and R 7 are independently selected from hydrogen or loweralkyl; and R 6 is hydrogen, loweralkyl, vinyl, arylalkyl or wherein R 8 is hydrogen or loweralkyl, X is O, NH or S and R 9 is hydrogen, loweralkyl or alkanoyl or XR 9 together can be loweralkylsulfonyl, N 3 or Cl.
    • 本发明涉及下式的肾素抑制化合物:其中R 10是A是氢或N-保护基; w是0或1; B是氢,羟基,NH,N-烷基,低级烷基或芳基烷基; 条件是当w为1时,B为NH且当w为0时,B为氢,羟基,低级烷基或芳基烷基; R1是低级烷基或亲脂性或芳族或亲水性氨基酸侧链; m是1-3; n是1-3; p是1-3; q是1-3; s是1-3; t是0-2; R2是氢或低级烷基; R3和R4独立地选自低级烷基,亲脂性或芳族氨基酸侧链; R5和R7独立地选自氢或低级烷基; 且R6为氢,低级烷基,乙烯基,芳基烷基或其中R8为氢或低级烷基,X为O,NH或S且R9为氢,低级烷基或烷酰基或XR9一起可为低级烷基磺酰基,N3或Cl。
    • 10. 发明公开
    • Functionalized peptidyl aminodiols and -triols
    • 磷脂酰胺和三聚氰胺。
    • EP0230266A2
    • 1987-07-29
    • EP87100422.2
    • 1987-01-15
    • ABBOTT LABORATORIES
    • Rosenberg, Saul HowardPlattner, Jacob JohnLuly, Jay Richard
    • C07K5/06C07K5/02C07K5/08C07D233/64A61K31/415A61K37/02A61K37/64
    • C07D233/64A61K38/00C07K5/0227C07K5/06043C07K5/06078C07K5/0806
    • The invention relates to renin inhibiting compounds of the formula
      wherein A is hydrogen; loweralkyl; arylalkyl; OR₈ or SR₈ wherein R₈ is hydrogen, loweralkyl or aminoalkyl; NR₉R₁₀ wherein R₉ and R₁₀ are independently selected from hydrogen, loweralkyl, aminoalkyl, cyanoalkyl and hydroxyalkyl;
      wherein B is NH, alkylamino, S, O, CH₂ or CHOH and R₁₁ is loweralkyl, cycloalkyl, aryl, arylalkyl, alkoxy, alkenyloxy, hydroxyalkoxy, dihydroxyalkoxy, arylalkoxy, arylalkoxyalkyl, amino, alkylamino, dialkylamino, (hydroxyalkyl)(alkyl)amino, (dihydroxy­alkyl)(alkyl)amino, carboxylic acid-substituted alkyl, alkoxycarbonylalkyl, aminoalkyl, N-protected aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, (N-protected)­ alkyl)aminoalkyl, (heterocyclic)alkyl or a substituted or unsubstituted heterocyclic; R₁ is loweralkyl, cycloalkylmethyl, benzyl, α-methylbenzyl, α, α-di­methylbenzyl, 4-methoxybenzyl, halobenzyl, (1-naphthyl)­methyl, (2-naphthyl)methyl, (4-imidazoyl)methyl, phenethyl, phenoxy, thiophenoxy or anilino; provided if R₁ is phenoxy, thiophenoxy or anilino, B is CH₂ or CHOH or A is hydrogen; R₃ is loweralkyl, benzyl or heterocyclic ring-substituted methyl; R₄ is lower­alkyl, cycloalkyl- methyl or benzyl; R₂, R₅ and R₆ are independently hydrogen or loweralkyl; X is O, NH or S; R₇ is hydrogen, loweralkyl, alkanoyl, alkylsulfonyl.
      wherein R₁₂ and R₁₃ are independently hydrogen or loweralkyl, n is 0-2 and R₁₄ is substituted or unsubstituted penyl or heterocyclic; or XR₇ together are loweralkylsulfonyl, N₃ or Cl, and pharmaceutically acceptable salts thereof.
    • 本发明涉及式:CHEM的肾素抑制化合物,其中A是氢; 低级烷基; 芳; OR8或SR8,其中R8是氢,低级烷基或氨基烷基; NR 9 R 10,其中R 9和R 10独立地选自氢,低级烷基,氨基烷基,氰基烷基和羟烷基; 其中B是NH,烷基氨基,S,O,CH 2或CHOH,R 11是低级烷基,环烷基,芳基,芳基烷基,烷氧基,烯氧基,羟基烷氧基,二羟基烷氧基,芳基烷氧基,芳基烷氧基烷基,氨基,烷基氨基,二烷基氨基,(羟基烷基) 烷基)氨基,(二羟基烷基)(烷基)氨基,羧酸取代的烷基,烷氧基羰基烷基,氨基烷基,N-保护的氨基烷基,烷基氨基烷基,二烷基氨基烷基,(N-保护的)烷基)氨基烷基,(杂环)烷基或取代或未取代的杂环 ; R1是低级烷基,环烷基甲基,苄基,α-甲基苄基,α,α-二甲基苄基,4-甲氧基苄基,卤代苄基,(1-萘基)甲基,(2-萘基)甲基,(4-咪唑基)甲基,苯乙基,苯氧基, 或anilino; 如果R1是苯氧基,硫代苯氧基或苯胺基,B是CH 2或CHOH或A是氢; R3是低级烷基,苄基或杂环环取代的甲基; R4是低级烷基,环烷基 - 甲基或苄基; R2,R5和R6独立地是氢或低级烷基; X是O,NH或S; R 7是氢,低级烷基,烷酰基,烷基磺酰基。 其中R 12和R 13独立地为氢或低级烷基,n为0-2,R 14为取代或未取代的吡啶基或杂环基; 或XR7一起是低级烷基磺酰基,N 3或Cl,及其药学上可接受的盐。